Target intelligence / Profile preview

Off-target genomic adenine

Molecular classification
Nucleic acid, Genomic DNA
01

Overview

Off-target genomic adenine within double-stranded DNA at near-match protospacer sites with NRCH PAMs refers to unintended sites of genetic modification by Adenine Base Editors (ABEs) utilizing engineered Cas9 variants. These variants, such as SpCas9-NRCH, are designed to recognize a broader range of Protospacer Adjacent Motifs (PAMs) beyond the standard NGG, specifically NRCH (where R is A/G and H is A/C/T) (Miller et al., 2020, Nature Biotechnology). When an ABE is directed to a target site, it may also bind to and deaminate adenines at "near-match" genomic locations that share high sequence homology with the guide RNA (Gaudelli et al., 2017, Nature). This process converts adenine to inosine, which is subsequently treated as guanine by DNA polymerase, resulting in permanent A•T-to-G•C transitions (Rees & Liu, 2018, Nature Reviews Genetics). Such off-target activity is a primary safety concern in genome editing, as it can lead to deleterious mutations, loss of tumor suppressor function, or activation of oncogenes (Zuo et al., 2019, Science). Consequently, identifying and quantifying these sites using high-throughput sequencing methods like GUIDE-seq or DISCOVER-seq is essential for the clinical translation of base editing technologies (Wienert et al., 2019, Science).

Other names
Off-target genomic adenine within double-stranded DNA at near-match protospacer sites with NRCH PAMsOff-target A•T-to-G•C conversionNon-specific adenine deaminationSpCas9-NRCH off-target siteNear-match protospacer adenine
02

Mechanism of action

Unintended adenosine deamination by a CRISPR-guided base editor at non-target genomic loci, leading to A-to-G transitions.

03

Biological functions

Other
04

Disease associations

CancerOther
05

Safety considerations

GenotoxicityOncogene activationTumor suppressor inactivationChromosomal instabilityUnintended phenotypic changes
06

Interacting drugs

Adenine Base Editor (ABE)

2 more in the full profile.

07

Biomarkers

GUIDE-seqCIRCLE-seqDigenome-seqDISCOVER-seqWhole-genome sequencing (WGS)

Beyond the preview

Go deeper on Off-target genomic adenine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Off-target genomic adenine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call